CFI-400945

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
01220142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Polo-like kinase 4 (PLK4) is a serine/threonine kinase regulating centriole duplication. CFI-400945 is a highly selective PLK4… (More)
Is this relevant?
2017
2017
BACKGROUND Polo-like kinase 4 (PLK4) plays a key role in centriole replication. Hence PLK4 inhibition disrupts mitosis, and… (More)
Is this relevant?
2017
2017
PURPOSE Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to… (More)
Is this relevant?
2016
2016
Corrigendum to “Discovery of orally active anticancer candidate CFI400945 derived from biologically promising spirooxindoles… (More)
Is this relevant?
Review
2016
Review
2016
The utility of natural products for identifying anticancer agents has been highly pursued in the last decades and over 100 drug… (More)
Is this relevant?
2015
2015
Previous publications from our laboratory have introduced novel inhibitors of Polo-like kinase 4 (PLK4), a mitotic kinase… (More)
Is this relevant?
Review
2015
Review
2015
The identification of novel anticancer agents with high efficacy and low toxicity has always been an intriguing topic in… (More)
Is this relevant?
2014
2014
PLK4 was identified as a promising therapeutic target through a systematic approach that combined RNAi screening with gene… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
  • Cancer discovery
  • 2014
CFI-400945 is a potent, selective, orally bioavailable PLK4 inhibitor with antitumor activity in vivo. 
Is this relevant?